Compare
Vyome Holdings, Inc vs Allarity Therapeutics, Inc. vs Can-Fite BioPharma Ltd. vs Medicinova Inc
| Latest fiscal year | Vyome Holdings, Inc HIND | Allarity Therapeutics, Inc. ALLR | Can-Fite BioPharma Ltd. CANF | Medicinova Inc MNOV |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $319.7K | $320.0K | $405.0K | $409.7K |
| Revenue growth (YoY) | +24.4% | n/a | -39.9% | n/a |
| Gross margin | 68.4% | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$10.26M | -$11.23M | -$9.83M | -$12.00M |
| EPS (Diluted) | -$4.86 | n/a | -$5.97 | -$0.24 |
| Operating cash flow | -$3.75M | -$14.82M | -$8.95M | -$9.81M |
| Free cash flow | n/a | -$14.83M | -$8.95M | -$9.81M |
| Cash & equivalents | $4.98M | $14.69M | $5.53M | $30.81M |
| Total assets | $6.50M | $18.26M | $9.51M | $45.60M |
| Total liabilities | $2.74M | $8.43M | n/a | $4.02M |
| Shareholders' equity | $3.76M | $9.83M | $5.59M | $41.59M |
| Return on year-end equity | -272.8% | -114.3% | -175.8% | -28.9% |
| Shares outstanding | 5.92M | 16.08M | 2.62M | 49.22M |
Revenue, most recent five fiscal years
| Fiscal year | Vyome Holdings, Inc | Allarity Therapeutics, Inc. | Can-Fite BioPharma Ltd. | Medicinova Inc |
|---|---|---|---|---|
| Latest | $319.7K Ended 2025-12-31 | $320.0K Ended 2025-12-31 | $405.0K Ended 2025-12-31 | $409.7K Ended 2025-12-31 |
| 1 year earlier | $256.9K Ended 2024-12-31 | $0 Ended 2024-12-31 | $674.0K Ended 2024-12-31 | n/a |
| 2 years earlier | $8.68M Ended 2023-12-31 | n/a | $743.0K Ended 2023-12-31 | $1.00M Ended 2023-12-31 |
| 3 years earlier | $11.24M Ended 2022-12-31 | n/a | $810.0K Ended 2022-12-31 | n/a |
| 4 years earlier | $13.60M Ended 2021-12-31 | n/a | $853.0K Ended 2021-12-31 | $4.04M Ended 2021-12-31 |